Abstract:The development of novel therapeutics for cancer immunotherapy is tightly restricted by using human samples to estimate the drug toxicity before moving to clinical trials. Currently numerous tumor-bearing animal models have been utilized to test the efficacy of anti-tumor drugs. However, the success rate remains low in the development of clinical treatment. One prominent reason is that the utilized animal models could not accurately predict the toxic response of human immune system to the drugs. Thus, establishing a predictive nonclinical animal platform that can detect potential unwanted toxicity to human patient will be critical for improving the safety of immune drug development. Previously, we have demonstrated a disseminated tumor-bearing humanized mouse model that can evaluate the toxicity and efficacy of bispecific T cell engager (BiTE). Here we aim to develop a novel tumor-bearing mouse model that can simultaneously evaluate the long-term efficacy against solid tumor in addition to cytokine level assessment. In this study, we co-engrafted disseminated and solid tumor cells to the same mice and compared with mice engrafted with disseminated tumor or solid tumor. Three donors were tested. Method: Human triple negative breast cancer MDA-MB-231/Luciferase-2A-GFP (MDA) cell line is epidermal growth factor receptor (EGFR) positive and is labeled with luciferin. The cells were implanted into PBMC humanized NSG-MHC class I/II double knock out (DKO) mice via orthotopic injection into mammary fat pad (MFP, 5x10 6 cells/mouse) and/or via intravenous (IV, 1x10 6/mouse) injection. Disseminated MDA cells normally colonize lung of mice after IV injection. Following EGFRxCD3 BiTE dosing initiation, tumor burden in MFP and lung were evaluated by a in vivo Xenogen imaging system, and solid tumor volume in MFP was measured 2 to 3 times a week by a digital caliper. To evaluate the toxicity levels in response to EGFRxCD3 BiTE treatment, the level of inflammatory cytokine levels in serum of mice were analyzed by BD cytometric bead array. Clinical observations, body weight change, and human immune cell activation were also monitored for drug toxicity assessment. Results: EGFRxCD3 BiTE treatment induced elevated human inflammatory cytokines in serum from humanized mice implanted with combined MFP and IV tumor. By comparison, the serum cytokine levels were low in mice implanted with MDA cells via MFP alone, suggesting that IV injection of tumor cells is required for cytokine production induced by EGFRxCD3 BiTE. MFP solid tumor continued to grow in the PBS control group and EGFRxCD3 BiTE treatments significantly inhibited solid tumor growth regardless the presence of IV implanted with MDA cells. Conclusion: Without disseminated tumor, MFP solid tumor-bearing mice served as a model for efficacy but did not produce inflammatory cytokines after treatment with EGFRxCD3 BiTE. Combination of solid and disseminated tumor implantation provides a new tumor inoculation approach that can be used for simultaneously evaluating the toxic cytokine release and long-term efficacy of immunotherapy drugs. This is a promising preclinical platform to define optimal approaches for clinical cancer treatment.

Human T Lymphocyte Responses Against Lung Cancer Induced by Recombinant Truncated Mouse EGFR

Humoral Immunity Responses Against EGFR-positive Tumor Cells Induced by Xenogeneic EGFR Expressed in the Yeast Pichia Pastoris.

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

Immunotherapy of EGFR-positive Tumor Based on Recombinant EGFR Phage Vaccine

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses

Active Immunotherapy of Tumors with a Recombinant Xenogeneic Endoglin As a Model Antigen.

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

[Immunotherapeutic Effect of Recombinant EGFR Phage Vaccine on Tumors].

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

Abstract 6718: Evaluating toxicity and efficacy of bispecific EGFRXCD3 T cell engager in solid tumor-bearing humanized animal model

Development of a Novel Solid Tumor-Bearing Humanized Animal Model for Simultaneously Evaluating the Toxicity and Efficacy of Bispecific T Cell Engager

Anti-tumor Immune Response Against Mouse Melanoma to Xenogeneic Vaccination

Active Antitumor Immunity Elicited by Vaccine Based on Recombinant Form of Epidermal Growth Factor Receptor

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

Transduction of the Gene Coding for A Human G-Protein Coupled Receptor Fprl1 in Mouse Tumor Cells Increases Host Anti-Tumor Immunity

Abstract 5345: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses